Advertisement

Orthopädie & Rheuma

, Volume 21, Issue 5, pp 34–40 | Cite as

Wichtiges zur Therapie vor, während und nach der Schwangerschaft

Rheumakranke Frauen: Kinderwunsch ist heutzutage meist erfüllbar

  • Dieter Schöffel
Fortbildung
  • 13 Downloads

Viele entzündliche Rheumaerkrankungen kommen bei Frauen häufiger vor als bei Männern. Manche dieser Erkrankungen beginnen oft im sogenannten gebärfähigen Alter. Dazu zählen unter anderen die rheumatoide Arthritis und der systemische Lupus erythematodes oder das axiale Befallsmuster der Spondyloarthritis. Modernen Therapieoptionen ist es zu verdanken, dass eine entzündlich rheumatische Erkrankung einer Frau heutzutage dem Wusch nach Kindern nicht mehr entgegensteht.

Literatur

  1. 1.
    Chakravarty E, Clowse ME, Pushparajah DS, Mertens S, Gordon C. Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open 2014;4:1–10CrossRefGoogle Scholar
  2. 2.
    Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810CrossRefGoogle Scholar
  3. 3.
    Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539–49CrossRefGoogle Scholar
  4. 4.
    Jakobsson GL, Stephansson O, Askling J, Jacobsson LT. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis 2016;75:1838–42CrossRefGoogle Scholar
  5. 5.
    Hench PS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis, and intermittent hydrarthrosis. Proc Staff Meet Mayo Clinic 1938;13:161–7Google Scholar
  6. 6.
    Jethwa H, Lam S, Smith C, Giles I. Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis. Arthritis Rheumatol 2016; 68 (suppl 10). ACR abstract 1517Google Scholar
  7. 7.
    Jawaheer D, Zhu JL, Nohr AE, Olsen J. Time to pregnancy among women with rheumatoid arthritis. Arthritis Rheum 2011;63:1517–21CrossRefGoogle Scholar
  8. 8.
    Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 2015;74:1836–41CrossRefGoogle Scholar
  9. 9.
    Boots CE, Gustofson RL, Feinberg EC. Does methotrexate administration for ectopic pregnancy after in vitro fertilization impact ovarian reserve or ovarian responsiveness?. Fertil Steril 2013;100:1590–3CrossRefGoogle Scholar
  10. 10.
    Winger EE, Reed JL, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 2009;61:113–20CrossRefGoogle Scholar
  11. 11.
    Flint J, Panchal S, Hurell A, van der Venne M, Gayed M, Schreiber K et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSP and BHPR guideline on prescribing drugs in pregnancy and breastfeeding. Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016;55:1693–7CrossRefGoogle Scholar
  12. 12.
    Mitchell K, Kaul M, Clowse ME. The management of rheumatic diseases in Pregnancy. Scand J Reumatol 2010;39:99–108CrossRefGoogle Scholar
  13. 13.
    van den Brandt S, Zbinden A, Baeten D, Villiger PM, Ostensen M, Forger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther 2017;19:64–72CrossRefGoogle Scholar
  14. 14.
    Ostensen M, Brucato A, Carp H, Chambers C, Dolhain RJ, Doria A et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology (Oxford) 2011;50:657–64CrossRefGoogle Scholar
  15. 15.
    Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernandez-Diaz S, Park Y et al. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ 2017;356:j895CrossRefGoogle Scholar
  16. 16.
    Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J 2006;10:361–6CrossRefGoogle Scholar
  17. 17.
    Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 2014;53:1377–85CrossRefGoogle Scholar
  18. 18.
    Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breast-feeding. Rheumatology (Oxford) 2010;49:2225–7CrossRefGoogle Scholar
  19. 19.
    Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N; Network of French Pharmacovigilance Centers et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheum 2014;66:1101–10CrossRefGoogle Scholar
  20. 20.
    Mariette X, Forger F, Abraham B, Flynn AD, Molto A, Flipo RM et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study. Annual European Congress of Rheumatology in Madrid 2017; EULAR Abstract 17-1640Google Scholar
  21. 21.
    Clowse ME, Wolf DC, Golembesky A, Shaugnessy L, De Cuyper D, Froger F. Characteristics and outcomes of prospectively-reported pregnancies exposed to certolizumab pegol from a safety database. ACR/AHRP Annual Meeting 2015; Poster Session C, Abstract Number: 2523Google Scholar
  22. 22.
    Oliver A, Overton C. Diagnosis and management of miscarriage. Practitioner 2014;258:25–8PubMedGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects. Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 2008;57:1-5Google Scholar
  24. 24.
    Polachek A, Li S, Polachek IS, Chandran V, Gladman D. Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. Semin Arthritis Rheum 2017;46:740–5CrossRefGoogle Scholar
  25. 25.
    Clowse ME 2017 EULAR Poster SAT 046 und SAT 0119Google Scholar
  26. 26.
    Hotham N, Hotham A. Drugs in breastfeeding. Aust Prescr 2015;38:156–9CrossRefGoogle Scholar
  27. 27.
    Derendorf H, Ruebsamen K, Clarke L, Schaeffler A, Kirwan JR. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol 2013;53:326–33CrossRefGoogle Scholar
  28. 28.
    Guettrot-Imbert G, Costedoat-Chalumeau N, Tincani A. EULAR Textbook on Rheumatic Diseases, BMJ Publishing 2012Google Scholar
  29. 29.
    Flint J, Panchal S, Hurrell A et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016 Sep;55(9):1693-7. doi: 10.1093/rheumatology/kev404.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Osteologisches Zentrum (DVO)MannheimDeutschland

Personalised recommendations